Azurity sues Bionpharma over newly issued patent

Azurity Pharmaceuticals has sued Massachusetts drug company Bionpharma, claiming that its generic of Azurity’s Epaned product infringes on a brand new patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia-Pacific

Apotex and Strides to merge Australia generics business

15 May 2018 Canadian generics maker Apotex and India-based Strides Shasun will merge their Australian operations in a bid to create the leading player in the Australian generics pharmaceutical market.

Americas

Eli Lilly targets more than 30 generics in Effient patent case

17 March 2014 Eli Lilly has filed suit against more than 30 generic drug makers at the US District Court for the Southern District of Indiana for allegedly infringing three patents related to platelet inhibitor drug Effient (prasugrel).

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Azurity sues Bionpharma over newly issued patent

More on this story

Editor's picks

Editor's picks

More features